ConductScience.org, home

Paper41337752

Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability.

Wang M and 8 others. ACS Chem Biol, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability. Papers, record 41337752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41337752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability.
PubMed
Journal
ACS Chem Biol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-05-08
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang MMingqian
2He YYongLehttps://orcid.org/0000-0001-7274-535X
3Cohen SASiobhan A
4Strohm ARAmanda Rhttps://orcid.org/0009-0003-2334-9504
5Shetye GGaurihttps://orcid.org/0000-0001-6282-2833
6Franzblau SGScott Ghttps://orcid.org/0000-0002-8698-0243
7Walker SGStephen G
8Alley MRKM R K
9Tonge PJPeter Jhttps://orcid.org/0000-0003-1606-3471

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Mycobacterium tuberculosisMajor topic
Leucine-tRNA LigaseMajor topic
Antitubercular AgentsMajor topic
Boron CompoundsMajor topic
Enzyme InhibitorsMajor topic
Escherichia coli
Microbial Sensitivity Tests

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R35 GM149297NIGMS NIH HHSUnited StatesR35GM149297PubMed and NIHNIH RePORTER
T32 GM136572NIGMS NIH HHSUnited StatesT32GM136572PubMed and NIHNIH RePORTER
T32 GM148331NIGMS NIH HHSUnited StatesT32GM148331PubMed and NIHNIH RePORTER

Download CSV of grants

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122683997Structural dynamics of the aminoacylation and proofreading functional cycle of bacterial leucyl-tRNA synthetase.Nat Struct Mol Biol2012https://conductscience.org/library/papers/22683997PubMed
217588934An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.Science2007https://conductscience.org/library/papers/17588934PubMed
312384607A one-step method for in vitro production of tRNA transcripts.Nucleic Acids Res2002https://conductscience.org/library/papers/12384607PubMed
434097493In Vitro Profiling of Antitubercular Compounds by Rapid, Efficient, and Nondestructive Assays Using Autoluminescent Mycobacterium tuberculosis.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/34097493PubMed
536037447Structure-Kinetic Relationship Studies for the Development of Long Residence Time LpxC Inhibitors.J Med Chem2022https://conductscience.org/library/papers/36037447PubMed
636454354Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening.AMB Express2022https://conductscience.org/library/papers/36454354PubMed
723959225Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase.Sci Rep2013https://conductscience.org/library/papers/23959225PubMed
811709357Postantibiotic effects of antituberculosis agents alone and in combination.Antimicrob Agents Chemother2001https://conductscience.org/library/papers/11709357PubMed
927547299Correlating Drug-Target Kinetics and In vivo Pharmacodynamics: Long Residence Time Inhibitors of the FabI Enoyl-ACP Reductase.Chem Sci2016https://conductscience.org/library/papers/27547299PubMed
1029437618In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29437618PubMed
1138418662Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nat Rev Drug Discov2024https://conductscience.org/library/papers/38418662PubMed
1240170302Time-Dependent Inhibition of Leucyl-tRNA-Synthetase (LeuRS): Insight into Target Vulnerability.ACS Infect Dis2025https://conductscience.org/library/papers/40170302PubMed
1322975201Time-dependent, reversible, oxaborole inhibition of Escherichia coli leucyl-tRNA synthetase measured with a continuous fluorescence assay.Anal Biochem2012https://conductscience.org/library/papers/22975201PubMed
1434637487Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline.PLoS Pathog2021https://conductscience.org/library/papers/34637487PubMed
1528640596Drug-Target Kinetics in Drug Discovery.ACS Chem Neurosci2018https://conductscience.org/library/papers/28640596PubMed
1628953378Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656).J Med Chem2017https://conductscience.org/library/papers/28953378PubMed
1727503647Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.Antimicrob Agents Chemother2016https://conductscience.org/library/papers/27503647PubMed
1819561621Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli.Nat Chem Biol2009https://conductscience.org/library/papers/19561621PubMed
1931030171Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics.Curr Opin Chem Biol2019https://conductscience.org/library/papers/31030171PubMed
2032011855Correlating Drug-Target Residence Time and Post-antibiotic Effect: Insight into Target Vulnerability.ACS Infect Dis2020https://conductscience.org/library/papers/32011855PubMed

See all 39 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42250658The post antibiotic effect of streptogramins on gram-positive bacteria primarily arises from the type a component.Microb Pathog2026https://conductscience.org/library/papers/42250658PubMed
42018569Physiologic recovery of Mycobacterium tuberculosis from drug injury: A molecular study of post antibiotic effect in vitro and in vivo.PLoS Pathog2026https://conductscience.org/library/papers/42018569PubMed

Download CSV of cited by

Data3

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccessionSource
PDB7PQKPDB
PDB4AQ7PDB
PDB4ARIPDB

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41337752

GET https://conductscience.org/api/papers/v1/41337752/references?page=2